Management of late, recurrent, and resistant cytomegalovirus in transplant patients

Transplantation Reviews

Volumn 21, Issue 2, 2007, Pages 65-76

  Avery, Robin K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; BENZIMIDAVIR; CIDOFOVIR; FOSCARNET; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; VALGANCICLOVIR; VIRUS DNA;

ADJUVANT THERAPY; ALLOTRANSPLANTATION; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL ACTIVITY; BONE MARROW TRANSPLANTATION; CARDIAC ALLOGRAFT VASCULOPATHY; CELLULAR IMMUNITY; CLINICAL TRIAL; COMORBIDITY; CROSS RESISTANCE; CYTOMEGALOVIRUS INFECTION; DRUG COST; DRUG DOSE ESCALATION; DRUG SUBSTITUTION; DRUG URINE LEVEL; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; GENITAL ULCER; GRAFT RECIPIENT; GRAFT REJECTION; HEPATITIS C; HUMAN; HYPOGAMMAGLOBULINEMIA; IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; KIDNEY TRANSPLANTATION; LIVER DYSFUNCTION; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; ORGAN TRANSPLANTATION; PERSISTENT VIRUS INFECTION; PNEUMONIA; RECURRENCE RISK; RECURRENT INFECTION; RETINITIS; REVIEW; RHEUMATOID ARTHRITIS; SEROCONVERSION; SIDE EFFECT; UVEITIS; VIREMIA; VIRUS LOAD; VIRUS MUTATION; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS VIRULENCE;

EID: 34249732166     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2007.02.001     Document Type: Review

References (99)

1. Tolkoff-Rubin N.E., Fishman J.A., and Rubin R.H. The bidirectional relationship between cytomegalovirus and allograft injury. Transplant Proc 33 1-2 (2001) 1773-1775
2. Britt W. Human cytomegalovirus infections and mechanisms of disease. In: Reddehase M.J. (Ed). Cytomegaloviruses: molecular biology and immunology (2006), Caister Academic Press, Norfolk (UK) 1-28
3. Everett J.P., Hershberger R.E., Norman D.J., et al. Prolonged cytomegalovirus infection with viremia is associated with development of cardiac allograft vasculopathy. J Heart Lung Transplant 11 3 Pt 2 (1992) S133-S137
4. Arkonac B., Mauck K.A., Chou S., and Hosenpud J.D. Low multiplicity cytomegalovirus infection of human aortic smooth muscle cells increases levels of major histocompatibility complex class I antigens and induces a proinflammatory cytokine milieu in the absence of cytopathology. J Heart Lung Transplant 16 10 (1997) 1035-1045
5. Fishman J.A., and Rubin R.H. Infection in organ-transplant recipients. N Engl J Med 338 24 (1998) 1741-1751
6. Rubin R.H. Infection in the organ transplant recipient. In: Rubin R.H., and Young L.S. (Eds). Clinical approach to infection in the compromised host. 4th ed. (2002), Plenum Medical Book Company, New York
7. Gane E., Saliba F., Valdecasas G.J., et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 350 9093 (1997) 1729-1733
8. Flechner S.M., Avery R.K., Fisher R., et al. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 66 12 (1998) 1682-1688
9. Paya C., Humar A., Dominguez E., et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4 4 (2004) 611-620
10. Freeman R.B., Paya C., Pescovitz M.D., et al. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 78 12 (2004) 1765-1773
11. Zandberg M., de Maar E.F., Hofker H.S., Homan van der Heide J.J., Rosati S., and van Son W.J. Initial cytomegalovirus prophylaxis with ganciclovir: no guarantee for prevention of late serious manifestations of CMV after solid organ transplantation. Neth J Med 63 10 (2005) 408-412
12. Limaye A.P., Bakthavatsalam R., Kim H.W., et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 78 9 (2004) 1390-1396
13. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis 40 5 (2005) 704-708
14. Linnemann C.C., Dunn C.R., First M.R., Alvira M., and Schiff G.M. Late onset of fatal cytomegalovirus infection after renal transplantation. Primary or reactivation infection?. Arch Intern Med 138 8 (1978) 1247-1250
15. Slifkin M., Tempesti P., Poutsiaka D.D., and Snydman D.R. Late and atypical cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 33 7 (2001) E62-E68
16. Trimarchi H., Jordan R., Iotti A., et al. Late-onset cytomegalovirus-associated interstitial nephritis in a kidney transplant. Nephron 92 2 (2002) 490-494
17. Boobes Y., Al Hakim M., Dastoor H., Bernieh B., and Abdulkhalik S. Late cytomegalovirus disease with atypical presentation in renal transplant patients: case reports. Transplant Proc 36 6 (2004) 1841-1843
18. Shibolet O., Ilan Y., Kalish Y., et al. Late cytomegalovirus disease following liver transplantation. Transpl Int 16 12 (2003) 861-865
19. Hibberd P.L., Tolkoff-Rubin N.E., Cosimi A.B., et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 53 1 (1992) 68-72
20. Hibberd P.L., Tolkoff-Rubin N.E., Conti D., et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 123 1 (1995) 18-26
21. Razonable R.R., Rivero A., Rodriguez A., et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 184 11 (2001) 1461-1464
22. Reinke P., Fietze E., Ode-Hakim S., et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 344 8939-8940 (1994) 1737-1738
23. Humar A., Mazzulli T., Moussa G., et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 5 5 (2005) 1065-1070
24. Zeevi A., Morel P., Spichty K., et al. Clinical significance of CMV-specific T helper responses in lung transplant recipients. Hum Immunol 59 12 (1998) 768-775
25. Singh N., Zeevi A., Gayowski T., and Marino I.R. Late onset cytomegalovirus disease in liver transplant recipients: de novo reactivation in recurrent hepatitis C virus hepatitis. Transpl Int 11 4 (1998) 308-311
26. Corales R., Chua J., Mawhorter S., et al. Significant post-transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon?. Transpl Infect Dis 2 3 (2000) 133-139
27. Yamani M.H., Avery R.K., Mawhorter S.D., et al. Hypogammaglobulinemia following cardiac transplantation: a link between rejection and infection. J Heart Lung Transplant 20 4 (2001) 425-430
28. Goldfarb N.S., Avery R.K., Goormastic M., et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation 71 2 (2001) 242-246
29. Braun W.E., Avery R., Gifford Jr. R.W., and Straffon R.A. Life after 20 years with a kidney transplant: redefined disease profiles and an emerging nondiabetic vasculopathy. Transplant Proc 29 1-2 (1997) 247-249
30. Sarmiento E., Fernandez-Yanez J., Munoz P., et al. Hypogammaglobulinemia after heart transplantation: use of intravenous immunoglobulin replacement therapy in relapsing CMV disease. Int Immunopharmacol 5 1 (2005) 97-101
31. Yamani M.H., Avery R., Mawhorter S.D., et al. The impact of CytoGam on cardiac transplant recipients with moderate hypogammaglobulinemia: a randomized single-center study. J Heart Lung Transplant 24 11 (2005) 1766-1769
32. Mylonakis E., Kallas W.M., and Fishman J.A. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis 34 10 (2002) 1337-1341
33. Mossad S.B., Lard M.L., Krishnamurthi V., et al. Clinical and virological outcomes of adding leflunomide to ganciclovir or foscarnet for treatment of CMV viremia in transplant recipients. Abstract #2208. World Transplant Congress, Boston, MA (2006)
34. Humar A., Siegal D., Moussa G., and Kumar D. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. J Infect Dis 192 7 (2005) 1154-1157
35. In: Reddehase M.J. (Ed). Cytomegaloviruses: molecular biology and immunology (2006), Caister Academic Press, Norfolk (UK)
36. Simon C.O., Seckert C.K., Grzimek N.K.A., and Reddehase M.J. Murine model of cytomegalovirus latency and reactivation: the silencing/desilencing and immune sensing hypothesis. In: Reddehase M.J. (Ed). Cytomegaloviruses: molecular biology and immunology (2006), Caister Academic Press, Norfolk (UK)
37. Meier J.L., and Stinski M.F. Major immediate-early enhancer and its gene products. In: Reddehase M.J. (Ed). Cytomegaloviruses: molecular biology and immunology (2006), Caister Academic Press, Norfolk (UK)
38. Bain M., Reeves M., and Sinclair J. Regulation of human cytomegalovirus gene expression by chromatin remodeling. In: Reddehase M.J. (Ed). Cytomegaloviruses: molecular biology and immunology (2006), Caister Academic Press, Norfolk (UK)
39. Zeevi A., Spichty K., Banas R., et al. Clinical significance of cytomegalovirus-specific T helper responses and cytokine production in lung transplant recipients. Intervirology 42 5-6 (1999) 291-300
40. Singh N., Gayowski T., Wagener M.M., and Zeevi A. T-helper cell responses in liver transplant recipients: correlation with cytomegalovirus and other major infections. Transpl Infect Dis 6 2 (2004) 93-96
41. Sawyer M.D., Mayoral J.L., Gillingham K.J., Kramer M.A., and Dunn D.L. Treatment of recurrent cytomegalovirus disease in patients receiving solid organ transplants. Arch Surg 128 2 (1993) 165-169 [discussion 170]
42. Avery R., Stillwell P., Kirby T., et al. The disproportionate burden of CMV in lung transplant recipients. American Society of Transplant Physicians 16th Annual Meeting. Chicago (1997)
43. Emery V.C., Hassan-Walker A.F., Burroughs A.K., and Griffiths P.D. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. J Infect Dis 185 12 (2002) 1723-1728
44. Emery V.C. Investigation of CMV disease in immunocompromised patients. J Clin Pathol 54 2 (2001) 84-88
45. Emery V.C., Cope A.V., Bowen E.F., Gor D., and Griffiths P.D. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 190 2 (1999) 177-182
46. Emery V.C., Sabin C.A., Cope A.V., Gor D., Hassan-Walker A.F., and Griffiths P.D. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355 9220 (2000) 2032-2036
47. Humar A., Kumar D., Caliendo A.M., et al. Clinical impact of human herpesvirus 6 infection after liver transplantation. Transplantation 73 4 (2002) 599-604
48. Kidd I.M., Clark D.A., Sabin C.A., et al. Prospective study of human betaherpesviruses after renal transplantation: association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection. Transplantation 69 11 (2000) 2400-2404
49. Griffiths P.D., Clark D.A., and Emery V.C. Betaherpesviruses in transplant recipients. J Antimicrob Chemother 45 Suppl T3 (2000) 29-34
50. Mattes F.M., Hainsworth E.G., Geretti A.M., et al. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis 189 8 (2004) 1355-1361
51. van den Berg A.P., van Son W.J., Haagsma E.B., et al. Prediction of recurrent cytomegalovirus disease after treatment with ganciclovir in solid-organ transplant recipients. Transplantation 55 4 (1993) 847-851
52. Limaye A.P., Raghu G., Koelle D.M., Ferrenberg J., Huang M.L., and Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 185 1 (2002) 20-27
53. Humar A., Kumar D., Boivin G., and Caliendo A.M. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 186 6 (2002) 829-833
54. Falagas M.E., and Snydman D.R. Recurrent cytomegalovirus disease in solid-organ transplant recipients. Transplant Proc 27 5 Suppl 1 (1995) 34-37
55. Falagas M.E., Snydman D.R., Griffith J., Werner B.G., Freeman R., and Rohrer R. Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Clin Infect Dis 25 2 (1997) 314-317
56. Singh N., Wannstedt C., Keyes L., Gayowski T., Wagener M.M., and Cacciarelli T.V. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 79 1 (2005) 85-90
57. Diaz-Pedroche C., Lumbreras C., San Juan R., et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation 82 1 (2006) 30-35
58. Khoury J.A., Storch G.A., Bohl D.L., et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 6 9 (2006) 2134-2143
59. Mattes F.M., Hainsworth E.G., Hassan-Walker A.F., et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 191 1 (2005) 89-92
60. Aigner C., Jaksch P., Winkler G., et al. Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation. Wien Klin Wochenschr 117 13-14 (2005) 480-484
61. Zamora M.R., Nicolls M.R., Hodges T.N., et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 4 10 (2004) 1635-1642
62. Reed E.C., Bowden R.A., Dandliker P.S., Gleaves C.A., and Meyers J.D. Efficacy of cytomegalovirus immunoglobulin in marrow transplant recipients with cytomegalovirus pneumonia. J Infect Dis 156 4 (1987) 641-645
63. Emanuel D. Treatment of cytomegalovirus disease. Semin Hematol 27 2 Suppl 1 (1990) 22-27 [discussion 28-29]
64. Ljungman P., Engelhard D., Link H., et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis 14 4 (1992) 831-835
65. George M.J., Snydman D.R., Werner B.G., et al. Use of ganciclovir plus cytomegalovirus immune globulin to treat CMV pneumonia in orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG-Study Group. Transplant Proc 25 5 Suppl 4 (1993) 22-24
66. Zeevi A., Britz J.A., Bentlejewski C.A., et al. Monitoring immune function during tacrolimus tapering in small bowel transplant recipients. Transpl Immunol 15 1 (2005) 17-24
67. Cadillo-Chavez R., de Echegaray S., Santiago-Delpin E.A., et al. Assessing the risk of infection and rejection in Hispanic renal transplant recipients by means of an adenosine triphosphate release assay. Transplant Proc 38 3 (2006) 918-920
68. Kowalski R.J., Post D.R., Mannon R.B., et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 82 5 (2006) 663-668
69. Lee T.C., Goss J.A., Rooney C.M., et al. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transplant 20 6 (2006) 689-694
70. Limaye A.P., Corey L., Koelle D.M., Davis C.L., and Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356 9230 (2000) 645-649
71. Isada C.M., Yen-Lieberman B., Lurain N.S., et al. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Transpl Infect Dis 4 4 (2002) 189-194
72. Boivin G., Goyette N., Gilbert C., et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 189 9 (2004) 1615-1618
73. Drew W.L., Paya C.V., and Emery V. Cytomegalovirus (CMV) resistance to antivirals. Am J Transplant 1 4 (2001) 307-312
74. Limaye A.P. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 35 7 (2002) 866-872
75. Chou S.W. Cytomegalovirus drug resistance and clinical implications. Transpl Infect Dis 3 Suppl 2 (2001) 20-24
76. Drew W.L. Ganciclovir resistance: a matter of time and titre. Lancet 356 9230 (2000) 609-610
77. Lurain N.S., Ammons H.C., Kapell K.S., Yeldandi V.V., Garrity E.R., and O'Keefe J.P. Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor. Transplantation 62 4 (1996) 497-502
78. Chou S., Waldemer R.H., Senters A.E., et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis 185 2 (2002) 162-169
79. Lurain N.S., Bhorade S.M., Pursell K.J., et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis 186 6 (2002) 760-768
80. Erice A., Gil-Roda C., Perez J.L., et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 175 5 (1997) 1087-1092
81. Chou S., Marousek G., Guentzel S., et al. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis 176 3 (1997) 786-789
82. Scott G.M., Weinberg A., Rawlinson W.D., and Chou S. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob Agents Chemother 51 1 (2007) 89-94
83. Bainbridge J.W., Raina J., Shah S.M., Ainsworth J., and Pinching A.J. Ocular complications of intravenous cidofovir for cytomegalovirus retinitis in patients with AIDS. Eye 13 Pt 3a (1999) 353-356
84. Waldman W.J., Knight D.A., Blinder L., et al. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology 42 5-6 (1999) 412-418
85. Waldman W.J., Knight D.A., Lurain N.S., et al. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation 68 6 (1999) 814-825
86. Williams J.W., Mital D., Chong A., et al. Experiences with leflunomide in solid organ transplantation. Transplantation 73 3 (2002) 358-366
87. Avery R.K., Bolwell B.J., Yen-Lieberman B., et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant 34 12 (2004) 1071-1075
88. John G.T., Manivannan J., Chandy S., Peter S., and Jacob C.K. Leflunomide therapy for cytomegalovirus disease in renal allograft recepients. Transplantation 77 9 (2004) 1460-1461
89. John G.T., Manivannan J., Chandy S., et al. A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients. Transplant Proc 37 10 (2005) 4303-4305
90. Chou S., Marousek G.I., Senters A.E., Davis M.G., and Biron K.K. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J Virol 78 13 (2004) 7124-7130
91. Drew W.L., Miner R.C., Marousek G.I., and Chou S. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 37 2 (2006) 124-127
92. Chou S., and Marousek G.I. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob Agents Chemother 50 10 (2006) 3470-3472
93. Emery V.C. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 11 2 (2001) 83-86
94. Singh N., and Yu V.L. Severing the Gordian knot of prevention of cytomegalovirus in liver transplant recipients: the principle is the sword. Liver Transpl 11 8 (2005) 891-894
95. Marfori J.E., Exner M.M., Marousek G.I., Chou S., and Drew W.L. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. J Clin Virol 38 2 (2007) 120-125
96. Fishman J.A., Doran M.T., Volpicelli S.A., Cosimi A.B., Flood J.G., and Rubin R.H. Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients. Transplantation 69 3 (2000) 389-394
97. Humar A., Paya C., Pescovitz M.D., et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am J Transplant 4 4 (2004) 644-649
98. Avery R.K., Mossad S.B., Mawhorter S.D., et al. Reduction of late CMV after prophylaxis by a combined prophylaxis/pre-emptive therapy program in high-risk transplant recipients. Abstract #2138. World Transplant Congress. Boston, MA (2006)
99. La Rosa C., Limaye A.P., Krishnan A., Longmate J., and Diamond D.J. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 195 5 (2007) 633-644